Trial · NCT02579239
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 14 of 14
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Group A - FSHD | TEAEs | 4 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Group B - LGMD2B and FSHD | TEAEs | 14 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Group A - FSHD | SAEs | 0 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Group B - LGMD2B and FSHD | SAEs | 0 | Participants | |
| Number of Participants With a Clinically Significant Electrocardiogram (ECG) Abnormality Leading to a TEAE | Group A - FSHD | 0 | Participants | ||
| Number of Participants With a Clinically Significant Electrocardiogram (ECG) Abnormality Leading to a TEAE | Group B - LGMD2B and FSHD | 0 | Participants | ||
| Number of Participants With a Clinically Significant Pulmonary Function Event Resulting in a TEAE | Group A - FSHD | 0 | Participants | ||
| Number of Participants With a Clinically Significant Pulmonary Function Event Resulting in a TEAE | Group B - LGMD2B and FSHD | 0 | Participants | ||
| Number of Participants With a Clinical Laboratory Abnormality Leading to an AE | Group A - FSHD | 0 | Participants | ||
| Number of Participants With a Clinical Laboratory Abnormality Leading to an AE | Group B - LGMD2B and FSHD | 4 | Participants | ||
| Number of Participants With Vital Sign Abnormality Resulting in a TEAE | Group A - FSHD | 0 | Participants | ||
| Number of Participants With Vital Sign Abnormality Resulting in a TEAE | Group B - LGMD2B and FSHD | 3 | Participants | ||
| Percent Change From Baseline in Manual Muscle Testing (MMT) Score at Week 14 | Group A - FSHD | -7.1 | Standard Deviation 13.38 | percent change | |
| Percent Change From Baseline in Manual Muscle Testing (MMT) Score at Week 14 | Group B - LGMD2B and FSHD | 4.3 | Standard Deviation 6.42 | percent change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02579239/results